Ensysce Biosciences, Inc.

For the period ended Jun 30, 2025. Filed Aug 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 13, 2025

ENSC$0.36+10.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Federal grants	$1,371,438	$181,797	$2,691,210	$487,519
Operating expenses:
Research and development	1,923,430	947,229	3,808,957	1,726,133
General and administrative	1,198,523	1,190,010	2,600,279	2,559,791
Total operating expenses	3,121,953	2,137,239	6,409,236	4,285,924
Loss from operations	(1,750,515)	(1,955,442)	(3,718,026)	(3,798,405)
Other income (expense):
Change in fair value of liability classified warrants	(853)	7,818	9,063	16,773
Interest expense, net	(3,160)	(27,563)	(7,017)	(1,275,628)
Other income and expense, net	21,011	7,394	36,890	(27,096)
Total other income (expense), net	16,998	(12,351)	38,936	(1,285,951)
Net loss	$(1,733,517)	$(1,967,793)	$(3,679,090)	$(5,084,356)
Net loss attributable to noncontrolling interests	(166)	-	(166)	(74)
Deemed dividend related to warrants down round provision	-	-	-	290
Net loss attributable to common stockholders	$(1,733,351)	$(1,967,793)	$(3,678,924)	$(5,084,572)
Net loss per basic and diluted share:
Net loss per share attributable to common stockholders, basic and diluted	$(0.79)	$(3.35)	$(2.04)	$(9.98)
Weighted average common shares outstanding, basic and diluted	2,202,299	587,822	1,803,393	509,347

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.